UBS Group
CGTX icon

UBS Group’s Cognition Therapeutics CGTX Stock Holding History

UBS Group’s Portfolio CGTX Stock Details CGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$58.3K Buy
76,873
+2,541
+3% +$2.96K ﹤0.01% 7279
2025
Q4 		$100K Buy
74,332
+8,293
+13% +$13.5K ﹤0.01% 6909
2025
Q3 		$89.2K Buy
66,039
+54,784
+487% +$74.7K ﹤0.01% 7203
2025
Q2 		$3.49K Buy
11,255
+11,254
+1,125,400% +$3.8K ﹤0.01% 9349
2025
Q1 		$0 Sell
1
-41,111
-100% -$24.2K ﹤0.01% 10270
2024
Q4 		$28.8K Sell
41,112
-156,747
-79% -$77.5K ﹤0.01% 7635
2024
Q3 		$92.8K Buy
+197,859
New +$204K ﹤0.01% 6424
2023
Q3 		– Sell
-610
Closed -$1.12K – 9513
2023
Q2 		$1.12K Buy
+610
New +$1.29K ﹤0.01% 8009
2023
Q1 		– Sell
-5,543
Closed -$11.6K – 9661
2022
Q4 		$11.6K Buy
5,543
+2,358
+74% +$4.76K ﹤0.01% 8373
2022
Q3 		$6K Buy
3,185
+2,286
+254% +$4.76K ﹤0.01% 9008
2022
Q2 		$2K Sell
899
-2,850
-76% -$7.36K ﹤0.01% 9517
2022
Q1 		$10K Hold
3,749
– – ﹤0.01% 8398
2021
Q4 		$24K Buy
+3,749
New +$36.6K ﹤0.01% 7622

Other funds holding CGTX

BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.32B AUM 15.59% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
DIG
Dauntless Investment Group Etna, New Hampshire $151M AUM 76.14% 1-Year Est. Return

UBS Group's CGTX Position: Q1 2026 in Review

UBS Group increased its Cognition Therapeutics (CGTX) stake by 3.4% in Q1 2026, buying an estimated $2.96K and bringing the position to 76,873 shares worth $58.3K. The position accounts for ﹤0.01% of the portfolio, ranked #7279.

UBS Group first reported a position in CGTX in Q4 2021 and has held it in 13 quarters since. The position peaked at $100K in Q4 2025. 75 funds tracked by Wall St. Rank hold CGTX as of Q1 2026.

  • UBS Group held 76,873 shares of Cognition Therapeutics worth $58.3K as of Q1 2026.
  • UBS Group bought 2,541 Cognition Therapeutics shares in Q1 2026, an estimated $2.96K.
  • Cognition Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #7279 holding.
  • UBS Group first reported a position in Cognition Therapeutics in Q4 2021 and has held it in 13 quarters since.
  • UBS Group's Cognition Therapeutics position peaked at $100K in Q4 2025.
  • 75 funds tracked by Wall St. Rank held Cognition Therapeutics as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.